98 related articles for article (PubMed ID: 29061645)
1. Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.
Garsed DW; Alsop K; Fereday S; Emmanuel C; Kennedy CJ; Etemadmoghadam D; Gao B; Gebski V; Garès V; Christie EL; Wouters MCA; Milne K; George J; Patch AM; Li J; Arnau GM; Semple T; Gadipally SR; Chiew YE; Hendley J; Mikeska T; Zapparoli GV; Amarasinghe K; Grimmond SM; Pearson JV; Waddell N; Hung J; Stewart CJR; Sharma R; Allan PE; Rambau PF; McNally O; Mileshkin L; Hamilton A; Ananda S; Grossi M; Cohen PA; Leung YC; Rome RM; Beale P; Blomfield P; Friedlander M; Brand A; Dobrovic A; Köbel M; Harnett P; Nelson BH; Bowtell DDL; deFazio A;
Clin Cancer Res; 2018 Feb; 24(3):569-580. PubMed ID: 29061645
[No Abstract] [Full Text] [Related]
2. Concurrent RB1 loss and
Saner FAM; Takahashi K; Budden T; Pandey A; Ariyaratne D; Zwimpfer TA; Meagher NS; Fereday S; Twomey L; Pishas KI; Hoang T; Bolithon A; Traficante N; Alsop K; Christie EL; Kang EY; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Alsop J; Beckmann MW; Boros J; Brand AH; Brooks-Wilson A; Carney ME; Coulson P; Courtney-Brooks M; Cushing-Haugen KL; Cybulski C; El-Bahrawy MA; Elishaev E; Erber R; Gayther SA; Gentry-Maharaj A; Blake Gilks C; Harnett PR; Harris HR; Hartmann A; Hein A; Hendley J; ; Hernandez BY; Jakubowska A; Jimenez-Linan M; Jones ME; Kaufmann SH; Kennedy CJ; Kluz T; Koziak JM; Kristjansdottir B; Le ND; Lener M; Lester J; Lubiński J; Mateoiu C; Orsulic S; Ruebner M; Schoemaker MJ; Shah M; Sharma R; Sherman ME; Shvetsov YB; Singh N; Rinda Soong T; Steed H; Sukumvanich P; Talhouk A; Taylor SE; Vierkant RA; Wang C; Widschwendter M; Wilkens LR; Winham SJ; Anglesio MS; Berchuck A; Brenton JD; Campbell I; Cook LS; Doherty JA; Fasching PA; Fortner RT; Goodman MT; Gronwald J; Huntsman DG; Karlan BY; Kelemen LE; Menon U; Modugno F; Pharoah PDP; Schildkraut JM; Sundfeldt K; Swerdlow AJ; Goode EL; DeFazio A; Köbel M; Ramus SJ; Bowtell DDL; Garsed DW
medRxiv; 2023 Nov; ():. PubMed ID: 37986741
[TBL] [Abstract][Full Text] [Related]
3. Elevated GALNT10 expression identifies immunosuppressive microenvironment and dismal prognosis of patients with high grade serous ovarian cancer.
Zhang G; Lu J; Yang M; Wang Y; Liu H; Xu C
Cancer Immunol Immunother; 2020 Feb; 69(2):175-187. PubMed ID: 31853576
[TBL] [Abstract][Full Text] [Related]
4. Concurrent RB1 Loss and BRCA-Deficiency Predicts Enhanced Immunological Response and Long-Term Survival in Tubo-Ovarian High-Grade Serous Carcinoma.
Saner FAM; Takahashi K; Budden T; Pandey A; Ariyaratne D; Zwimpfer TA; Meagher NS; Fereday S; Twomey L; Pishas KI; Hoang T; Bolithon A; Traficante N; Alsop K; Christie EL; Kang EY; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Alsop J; Beckmann MW; Boros J; Brand AH; Brooks-Wilson A; Carney ME; Coulson P; Courtney-Brooks M; Cushing-Haugen KL; Cybulski C; El-Bahrawy M; Elishaev E; Erber R; Gayther SA; Gentry-Maharaj A; Gilks CB; Harnett PR; Harris HR; Hartmann A; Hein A; Hendley J; Hernandez BY; Jakubowska A; Jimenez-Linan M; Jones ME; Kaufmann SH; Kennedy CJ; Kluz T; Koziak JM; Kristjansdottir B; Le ND; Lener M; Lester J; Lubiński J; Mateoiu C; Orsulic S; Ruebner M; Schoemaker MJ; Shah M; Sharma R; Sherman ME; Shvetsov YB; Soong TR; Steed H; Sukumvanich P; Talhouk A; Taylor SE; Vierkant RA; Wang C; Widschwendter M; Wilkens LR; Winham SJ; Anglesio MS; Berchuck A; Brenton JD; Campbell I; Cook LS; Doherty JA; Fasching PA; Fortner RT; Goodman MT; Gronwald J; Huntsman DG; Karlan BY; Kelemen LE; Menon U; Modugno F; Pharoah PDP; Schildkraut JM; Sundfeldt K; Swerdlow AJ; Goode EL; DeFazio A; Köbel M; Ramus SJ; Bowtell DDL; Garsed DW
Clin Cancer Res; 2024 Jun; ():. PubMed ID: 38837893
[TBL] [Abstract][Full Text] [Related]
5. Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma.
Shi Z; Zhao Q; Lv B; Qu X; Han X; Wang H; Qiu J; Hua K
Clin Transl Med; 2021 May; 11(5):e399. PubMed ID: 34047476
[TBL] [Abstract][Full Text] [Related]
6. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature.
Hinchcliff E; Paquette C; Roszik J; Kelting S; Stoler MH; Mok SC; Yeung TL; Zhang Q; Yates M; Peng W; Hwu P; Jazaeri A
Cancer Immunol Immunother; 2019 Sep; 68(9):1515-1526. PubMed ID: 31515669
[TBL] [Abstract][Full Text] [Related]
7. Improved overall survival in patients with high-grade serous ovarian cancer is associated with CD16a+ immunologic neighborhoods containing NK cells, T cells and macrophages.
Nersesian S; Arseneau RJ; Mejia JP; Lee SN; Westhaver LP; Griffiths NW; Grantham SR; Meunier L; Communal L; Mukherjee A; Mes-Masson AM; Arnason T; Nelson BH; Boudreau JE
Front Immunol; 2023; 14():1307873. PubMed ID: 38318505
[TBL] [Abstract][Full Text] [Related]
8. Location of Mutation in
Labidi-Galy SI; Olivier T; Rodrigues M; Ferraioli D; Derbel O; Bodmer A; Petignat P; Rak B; Chopin N; Tredan O; Heudel PE; Stuckelberger S; Meeus P; Meraldi P; Viassolo V; Ayme A; Chappuis PO; Stern MH; Houdayer C; Stoppa-Lyonnet D; Buisson A; Golmard L; Bonadona V; Ray-Coquard I
Clin Cancer Res; 2018 Jan; 24(2):326-333. PubMed ID: 29084914
[No Abstract] [Full Text] [Related]
9. High grade serous ovarian carcinomas originate in the fallopian tube.
Labidi-Galy SI; Papp E; Hallberg D; Niknafs N; Adleff V; Noe M; Bhattacharya R; Novak M; Jones S; Phallen J; Hruban CA; Hirsch MS; Lin DI; Schwartz L; Maire CL; Tille JC; Bowden M; Ayhan A; Wood LD; Scharpf RB; Kurman R; Wang TL; Shih IM; Karchin R; Drapkin R; Velculescu VE
Nat Commun; 2017 Oct; 8(1):1093. PubMed ID: 29061967
[TBL] [Abstract][Full Text] [Related]
10. Surviving Ovarian Cancer: An Affair between Defective DNA Repair and RB1.
Peng G; Mills GB
Clin Cancer Res; 2018 Feb; 24(3):508-510. PubMed ID: 29191971
[TBL] [Abstract][Full Text] [Related]
11. Defects in recombination activity caused by somatic and germline mutations in the multimerization/BRCA2 binding region of human RAD51 protein.
Silva MC; Bryan KE; Morrical MD; Averill AM; Dragon J; Wiegmans AP; Morrical SW
DNA Repair (Amst); 2017 Dec; 60():64-76. PubMed ID: 29100040
[TBL] [Abstract][Full Text] [Related]
12. PARPi focus the spotlight on replication fork protection in cancer.
Schlacher K
Nat Cell Biol; 2017 Oct; 19(11):1309-1310. PubMed ID: 29087384
[TBL] [Abstract][Full Text] [Related]
13. Who are the long-term survivors of high grade serous ovarian cancer?
Hoppenot C; Eckert MA; Tienda SM; Lengyel E
Gynecol Oncol; 2018 Jan; 148(1):204-212. PubMed ID: 29128106
[TBL] [Abstract][Full Text] [Related]
14. Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer.
Wang Y; Ung MH; Cantor S; Cheng C
Sci Rep; 2017 Nov; 7(1):15742. PubMed ID: 29146938
[TBL] [Abstract][Full Text] [Related]
15. Current status of poly(ADP-ribose) polymerase inhibitors and future directions.
Ohmoto A; Yachida S
Onco Targets Ther; 2017; 10():5195-5208. PubMed ID: 29138572
[TBL] [Abstract][Full Text] [Related]
16. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer.
Chou A; Froio D; Nagrial AM; Parkin A; Murphy KJ; Chin VT; Wohl D; Steinmann A; Stark R; Drury A; Walters SN; Vennin C; Burgess A; Pinese M; Chantrill LA; Cowley MJ; Molloy TJ; ; Waddell N; Johns A; Grimmond SM; Chang DK; Biankin AV; Sansom OJ; Morton JP; Grey ST; Cox TR; Turchini J; Samra J; Clarke SJ; Timpson P; Gill AJ; Pajic M
Gut; 2018 Dec; 67(12):2142-2155. PubMed ID: 29080858
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
van den Bent M; Gan HK; Lassman AB; Kumthekar P; Merrell R; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP; Penas-Prado M; Simes J; Wheeler H; Walbert T; Scott AM; Gomez E; Lee HJ; Roberts-Rapp L; Xiong H; Bain E; Ansell PJ; Holen KD; Maag D; Reardon DA
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1209-1217. PubMed ID: 29075855
[TBL] [Abstract][Full Text] [Related]
18. Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?
Berchuck A; Secord AA; Moss HA; Havrilesky LJ
J Clin Oncol; 2017 Dec; 35(36):3999-4002. PubMed ID: 29072978
[No Abstract] [Full Text] [Related]
19. Protein-coding genes, long non-coding RNAs combined with microRNAs as a novel clinical multi-dimension transcriptome signature to predict prognosis in ovarian cancer.
Meng X; Jin-Cheng G; Jue Z; Quan-Fu M; Bin Y; Xu-Feng W
Oncotarget; 2017 Sep; 8(42):72847-72859. PubMed ID: 29069830
[TBL] [Abstract][Full Text] [Related]
20. Acquired chemotherapy resistance in ovarian cancer.
Christie EL; Bowtell DDL
Ann Oncol; 2017 Nov; 28(suppl_8):viii13-viii15. PubMed ID: 29232469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
